



UPDATE IN INTENSIVE CARE MEDICINE: SEVERE INFECTIONS DUE TO MULTI-RESISTANT GRAM-NEGATIVE BACILLI

Treatment of severe infections caused by ESBL or carbapenemases-producing Enterobacteriaceae

G. Lombardi, E.S. Tanzarella, S.L. Cutuli, G. De Pascale*

Dipartimento di Scienze dell'emergenza, anesthesiologiche e della rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Received 17 August 2022; accepted 6 September 2022

Available online 3 October 2022

KEYWORDS

Enterobacteriaceae;
Multi-drug resistance;
Intensive care units

Abstract Enterobacteriaceae are the most frequent pathogens in the Intensive Care Unit. Due to their safety and activity, β -Lactams (BL) and carbapenems represented the most common strategy adopted against these germs. The increasing exposure to these molecules led to the development of several types of antimicrobial resistance as the expression of extended-spectrum β -lactamases (ESBLs) and carbapenemases. Great molecular variability exists among these enzymes, with significant clinical impact.

To limit morbidity and mortality, old antibiotics were tested and represent viable alternatives for specific types of infections, or once the spectrum of susceptibility of each germ has been determined. Alongside, new molecules have been specifically designed but enzyme molecular variability prevents the existence of one single antibiotic which fits for all.

Therefore, a quicker identification of the molecular identity of each germ, together with the knowledge of the activity spectrum of each antibiotic is crucial to tailor the therapy and make it effective.

© 2022 Published by Elsevier España, S.L.U.

PALABRAS CLAVE

Enterobacterias;
Multirresistencias;
Unidades de cuidados
intensivos

Tratamiento de las infecciones severas causadas por enterobacterias productoras de beta lactamasas de espectro extendido (BLEE) y carbapenemasas

Resumen Las enterobacterias son patógenos cada vez más frecuentes en las unidades de cuidados intensivos. Los antibióticos beta lactámicos y carbapenémicos representan las estrategias más comunes contra estos gérmenes, debido a sus mecanismos de acción y seguridad clínica. La exposición cada vez mayor de los patógenos a dichas moléculas ha llevado al desarrollo de nuevas diferentes resistencias a los antibióticos, representadas por la expresión de las beta lactamasas de espectro extendido y de las carbapenemasas. Esas enzimas manifiestan mucha variabilidad molecular, que resulta en un sustancial impacto clínico.

* Corresponding author.

E-mail address: gennaro.depascalemd@gmail.com (G. De Pascale).

Una opción disponible y válida para limitar la morbilidad y la mortalidad de estas infecciones es volver a utilizar los viejos antibióticos, una vez que se haya averiguado el espectro de sensibilidad de los gérmenes. Además, nuevos antibióticos han sido específicamente diseñados para solucionar el problema de las resistencias. Sin embargo, la variabilidad molecular de las enzimas hace que sea muy difícil encontrar una única molécula que funcione para todas.

Por lo tanto, una rápida identificación de la identidad molecular de los gérmenes, junto a la comprensión detallada del espectro de actividad de cada antibiótico, es de vital importancia para adaptar el tratamiento y hacerlo más efectivo.

© 2022 Publicado por Elsevier España, S.L.U.

Introduction

The emergence and wide spread of multi-drug resistant (MDR) pathogens represent a clinical challenge for patients, physicians and health care systems. In this setting, β -Lactams (BL) are the oldest and most frequently prescribed antibiotics in daily clinical practice, which extended use has been identified as the predominant determinant of acquired bacterial resistance towards these drugs.¹ Specifically, this condition was first described nearly 70 years ago in a strain of *Escherichia coli*, which was characterised by a specific hydrolytic enzyme that conferred resistance to β -Lactams, which was called β -Lactamases.²

In critical care practice, the EPIC III study³ reported that Gram-Negative bacteria and, specifically, the Enterobacteriaceae, were the most frequently isolated pathogens in critically ill patients admitted to the Intensive Care Unit (ICU) in 2017. Moreover, this study revealed that infections caused by Gram-Negative bacteria producing extended-spectrum β -lactamases (ESBLs) and carbapenemases were significant risk factors for hospital mortality. These findings were justified by the impact of MDR pathogens on the delivery of effective antimicrobial therapy, leading to delayed administration of appropriate antibiotics with consequent worse clinical outcomes.⁴ Furthermore, the use of carbapenems to treat infection caused by ESBLs-producing pathogens grew after the publication of the MERINO study,⁵ a randomised clinical trial that did not demonstrate the inferiority of piperacillin-tazobactam compared with meropenem.⁶ For these reasons, carbapenems sparing therapeutic option are strongly advocated and the World Health Organization listed the development of new effective drug on ESBL and carbapenemases-producing Enterobacteriaceae as a research priority in order to modulate the increased morbidity and mortality caused by such pathogens.⁷

In this paper, we reported an updated review of the literature on the mechanisms of resistance of ESBLs and carbapenemases-producing Enterobacteriaceae. Moreover, we provided an overview of therapeutic strategies for the management of severe infections caused by these pathogens with a brief presentation of “old” and “new” antibiotics used in this setting.

ESBL-producing Enterobacteriaceae

Mechanism of antibiotic resistance

ESBL represents a group of enzymes that hydrolyses and confers resistance to a variety of β -lactams, like third generation cephalosporines (i.e., cefotaxime, ceftriaxone and ceftazidime) and monobactams (i.e., aztreonam), with the exception of cephamycins (i.e., cefoxitin, cefotetan) and carbapenems (i.e., imipenem, meropenem, doripenem, ertapenem).⁸ This group accounts for several enzymes that may be classified according to the amino acid sequence homology into the “molecular” Ambler classes A to D.⁹ Although this classification is the most widely used in clinical practice, ESBLs may be graded according to the substrate and inhibitors profiles into the “functional” Bush-Jacoby-Medeiros groups 1, 2 and 3.¹⁰ From an epidemiological point of view, the majority of ESBLs belongs to the Ambler class A and are codified by the SHV, TEM and CTX-M genes. Over the past decades, *Klebsiella Pneumoniae* and *E. Coli* have been observed as the most common ESBLs-producing Enterobacteriaceae (ESBL-E) isolated worldwide from hospitals, among which CTX-M is prevalent.¹¹ Moreover, CTX-M derived ESBL-E have been identified in *E. coli* strains from community sites, for which co-resistance for other classes of antibiotics like cotrimoxazole, tetracycline, gentamicin, and ciprofloxacin was the main reason for therapeutic failure and worse clinical outcome when cephalosporins and fluoroquinolones were used as empirical antibiotics. Moreover, recent evidence reported that some SHV and TEM derived β -lactamases are characterized by amino acid substitutions that confer resistance to the β -lactamase inhibitors clavulanate and sulbactam, while remaining susceptible to tazobactam and avibactam.¹²

On top of that, the in-vitro efficacy of some β -lactams and β -lactamase inhibitor (BLBLI) may be limited by the “inoculum effect”, which is caused by the proportional relationship between the minimum inhibitory concentration and bacterial load.¹³ Finally, ESBL-E may have additional genes or mutations in genes that mediate resistance to a broad range of antibiotics (cotrimoxazole, tetracyclines, aminoglycosides, and fluoroquinolones), thus challenging the prescription of appropriate antibiotic therapy.¹⁴

Old molecules

Carbapenems represent the first choice to treat infections caused by ESBL-E because they are not susceptible to enzymatic hydrolysis, are well distributed at high concentration into body tissues and are not hampered by the inoculum effect. However, their pivotal role in the management of severe infections caused by ESBL-E has been questioned by high cost and the potential risk of favouring the growth of yeast and bacteria resistant to these antibiotics. Moreover, the superiority of carbapenems over other molecules remains mainly theoretical and supported by comparative studies with high risk of bias.⁸ Specifically, the INCREMENT study collected retrospective data on 1004 episodes of blood stream infections due to ESBL-producing Enterobacteriaceae from 7 tertiary hospitals in 11 different countries between 2004 and 2013.¹⁵ The authors found that BLBLI, aminoglycosides and fluoroquinolones were not inferior to carbapenems when pathogens showed in-vitro susceptibility to these drugs and such findings were supported by a recent systematic review and meta-analysis on 35 papers on this topic.¹⁶ Consequently, these antibiotics may represent an option for de-escalation of empiric antibiotic therapy as soon as the spectrum of pathogen susceptibility to antibiotics is detected and their early use may be favoured by the implementation of rapid diagnostic tools of genomic analyses.¹⁷ On the contrary, the MERINO randomised clinical trial compared the effect of piperacillin/tazobactam (4.5g every 6h) with meropenem (1g every 8h) for the treatment of bloodstream infections due to cephalosporin resistant Enterobacteriales in 379 patients from 26 hospitals in 9 countries between 2014 and 2017.⁵ The authors found that piperacillin/tazobactam was not non-inferior compared with meropenem with regards to 30-day mortality (12.3% vs. 3.7%, respectively; risk difference 8.6%, $p=0.9$ for noninferiority). However, the results of this trial were hampered by several drawbacks like the premature termination of the study and the wide post-hoc detected non-susceptibility of microbiological isolates to piperacillin-tazobactam. Specifically, in a MERINO subgroup analysis, Henderson et al.¹⁸ found a decreasing difference of absolute risk of 30-day mortality when piperacillin-tazobactam resistant strains were excluded. Nevertheless, a difference still exists and further trials are underway to elucidate this problem.¹⁹ As it stands, carbapenems use appears reasonable in patients with severe infections caused by ceftriaxone-resistant Enterobacteriaceae, although other therapeutic options should be driven by in-vitro spectrum of antibiotic susceptibility. Although meropenem is the most studied carbapenem, ertapenem is also indicated for ESBL-E pyelonephritis and complicated urinary tract infections, even though a randomized controlled trial demonstrated piperacillin-tazobactam non-inferiority.²⁰ Other antibiotics may play a role in the management of ESBL-producing Enterobacteriaceae, although their effect has never been tested in randomised clinical trials. As a matter of fact, cefepime, a fourth generation cephalosporine, shows potent in-vitro activity against these pathogens, although it is hampered by the “inoculum effect” and clinical studies showed that it was associated with higher treatment failure compared with carbapenems or piperacillin-tazobactam.^{20,21}

Apart from BLBLI, aminoglycosides and fluoroquinolones, other carbapenem-sparing options in the management of ESBL-E are represented by tigecycline, fosfomycin and trimethoprim-sulfamethoxazole. Tigecycline may play a role in intra-abdominal (IAI) and soft tissue infections (SSTI), although its low blood concentration limits its use for blood stream infection (BSI). On the contrary, high doses of fosfomycin (16–24g daily) appeared useful to treat urinary tract infections (UTI), but a recent randomised clinical trial did not demonstrate noninferiority of this drug compared with meropenem, mainly due to treatment discontinuation caused by the development of adverse event.²² Finally, trimethoprim-sulfamethoxazole is recommended by IDSA guidelines for the management of uncomplicated UTIs or eventual cUTI caused by ESBL-E that are not resistant to this drug.²³

New molecules

Over the past decade, new molecules as well as BL and carbapenems/BLI combinations have been implemented in clinical practice with the aim to treat severe infections caused by ESBL-E.

Among new molecules, ceftiderocol is a cephalosporine that penetrates the pathogen via an iron transporter and is currently approved from the treatment of complicated UTI.²⁴ Moreover, the two new tetracyclines, omadacycline and eravacycline, were approved for the treatment of community-acquired pneumonia, SSTI, and cIAI, although they have no activity against *Pseudomonas Aeruginosa*.²⁵ On the contrary, plazomicin is a novel aminoglycoside that has a broad-spectrum in vitro activity against Enterobacteriaceae and Gram-positive bacteria and was demonstrated non-inferior to levofloxacin and meropenem to treat cUTI.^{26,27}

New BLBLI combinations are represented by ceftazidime-avibactam and ceftolozane-tazobactam. Ceftazidime-avibactam is active against ESBLs (Ambler class A, C and D) Enterobacteriaceae and was demonstrated not inferior compared with carbapenems in the management of cIAI, cUTI, and nosocomial pneumonia.^{28–30}

Ceftolozane-tazobactam is a fifth-generation cephalosporin which is active against ESBL-E. At the moment, it represents the most active antibiotic against *Pseudomonas Aeruginosa* and was approved for the treatment of nosocomial pneumonia, UTI and IAI in combination with metronidazole.^{31–33}

Several subgroup or retrospective analyses confirm ceftolozane-tazobactam usefulness; clinical cure rate and microbiological response are equally high when compared to carbapenems.³⁴ However, in-vitro susceptibility widely varies depending on the population studied and the germs involved,³⁵ and frequent situations as septic shock and renal replacement therapy represent risk factors for non-response.³⁶ Those drugs have a potential role in a carbapenem-sparing point-of-view, but the observations reported are controversial, especially when in-vitro susceptibility is not available. Hence, a direct comparison of BLBLI to carbapenem in a randomized control trial is needed. In this perspective the MERINO-3 trial is comparing ceftolozane-tazobactam to meropenem in ESBL-E bloodstream infections with expected conclusion in 2024.³⁷

Finally, the new carbapenems/BLI combinations imipenem-relebactam and meropenem-vaborbactam may play a role in the management of severe infections caused by ESBLs-producing pathogens, although they represent the mainstay of therapy for carbapenemases-producing Enterobacteriaceae and will be described in detail over the next paragraphs.

Carbapenemases-producing Enterobacteriaceae

Mechanism of antibiotic resistance

Carbapenem-resistant Enterobacteriaceae (CRE) are defined as bacteria resistant to at least one carbapenem antibiotic or producing a carbapenemase enzyme.²³ Apart from carbapenemases, strategies for carbapenem-resistance include alterations to the target protein, an increase in efflux pumps or a decrease in membrane permeability.³⁸ Carbapenemase-producing Enterobacteriaceae account approximately for 85% of all CRE, with wide geographical variation.³⁹

Carbapenemases are protein which can break the molecular structure of antibiotics, avoiding their binding to the penicillin-binding protein. They are active against a variety of antibiotic classes, such as cephalosporins, penicillins, monobactams and carbapenems.⁴⁰ According to their molecular structure, carbapenemases are found within class A, B and D of the Ambler classification system.⁹ Discovered in 1996 in a *K. pneumoniae* isolate, KPC is the most frequent enzyme of Amber class A,⁴¹ has worldwide spread and is also expressed by other Enterobacteriaceae.⁴² Amber class B includes metallo- β -lactamases such as VIM, which is frequent in Southern Europe, IMP, accounting for 15% of CRE in Japan and Australia, and NDM which has the highest burden in Middle East and East Europe. OXA-48-like enzymes is a group of Ambler D class protein similar to OXA-48 enzyme, largely found in Acinetobacter. Variants in this group vary for geographical distribution and resistance spectrum, but they are found mostly in Northern Africa and Middle East.^{39,43}

Clinical indication for antibiotic treatment of CRE infections depends on germ susceptibility and type of carbapenemase expressed. Therefore, molecular identification is crucial for an appropriate antibiotic regimen (Fig. 1).

Old molecules

Since the emergence of MDR, together with the development of new active antibiotics, research found new application for well-known and safe molecules. In fact, CRE are susceptible to old classes of drugs like monobactams, polymyxins, tetracyclines, aminoglycosides and quinolones.

Tetracycline role is interesting as susceptibility to these agents is independent of the presence or type of carbapenemase.^{44,45} Both carbapenemase-producing (e.g., KPC, NDM, OXA-48-like carbapenemases) and non-carbapenemase-producing Enterobacteriaceae may be susceptible to these molecules. Tigecycline has very low rate of in-vitro resistance (<1,3% of Enterobacteriales isolates) but its role in clinical practice is limited by poor benefit as monotherapy and in combination.⁴⁶ Recent IDSA guide-

lines recommend tetracycline derivatives only as alternative options for IAI, SSTI, osteomyelitis and respiratory infections, when BL agents are inactive or not tolerated.²³ The rationale behind this recommendation is that their rapid tissue distribution results in a poor concentration in urine or serum, making their use for urinary and bloodstream infections inappropriate.

The optimal dosing has now been shown to be 200 mg intravenously as a single dose followed by 100 mg intravenously every 12 h.⁴⁷

Polymyxins, especially polymyxin E (colistin), have been widely used for CRE infections in the last twenty years, as a "revival" of old molecules in the era of multidrug resistant bacteria.^{48,49}

However, several observational studies and RCT demonstrated their inferiority compared to other CRE-active agents, due to increased mortality and nephrotoxicity^{50–52} (Table 1). Moreover, in-vitro efficacy to colistin can be often limited by the above mentioned "inoculum effect". Therefore, IDSA recommends against the use of intravenous polymyxins for the treatment of CRE infections, except for the uncomplicated CRE UTI, and only relating to polymyxin E (colistin)²³.

Besides its nephrotoxicity, intravenous administration of colistin results in lack of lung tissue penetration and is therefore not recommended as a drug of choice for nosocomial pneumonias caused by CRE. On the other hand, animal studies showed a higher lung tissue concentration and bactericidal effect of nebulized colistin administration, making sense out of its aerosol delivery. However, there is not strong evidence regarding the effects of nebulized antibiotics, supported only by small observational studies with conflicting findings.^{53,54} Although the European Society of Clinical Microbiology and Infectious Disease guidelines⁵⁵ recommend against adjunctive nebulized colistin in CRE-caused nosocomial pneumonia, the International Consensus Guidelines for the Optimal Use of the Polymyxins⁵⁶ raises the concern that the benefits may outweigh the risks, potentially laying the foundations for new recommendations.

In addition to colistin, fosfomycin, nitrofurantoin, aminoglycosides as gentamycin, amikacin and plazomicin and fluoroquinolones may be effective treatment options for uncomplicated UTIs caused by CRE.^{57,58}

Fosfomycin should be administered as a single oral dose only as a treatment for uncomplicated CRE cystitis caused by *E. Coli*, because the *fosA* gene (that characterizes *Klebsiella* spp., *Enterobacter* spp. and *Serratia Marcescens*) can hydrolyse the molecule leading to clinical failure.²³

Both nitrofurantoin and fosfomycin should be avoided for complicated UTI and pyelonephritis, due to their poor concentrations achieved in the renal parenchyma.

However, its in-vitro activity against CRE and other MDR bacteria leads to growing interest for intravenous use of this molecule.⁵⁹

Monobactams as aztreonam are effective only against bacteria producing class B or D carbapenemases, with no activity against bacteria producing class A carbapenemases, including the highly prevalent KPC carbapenemases.

Aztreonam is indicated as an adjunctive drug together with new BLBLI combination in CRE infection in which metallo- β -lactamases are recognized, such as Enterobacteriales producing NDM.




Fig. 1 Flow-chart of CRE infection management according to molecular identification. *Except uncomplicated urinary tract infections, CRE, Carbapenem resistant Enterobacteriaceae.

Although aztreonam is not hydrolyzed by NDMs, it should be avoided in monotherapy because ESBLs, AmpC β -lactamases and OXA-48-like carbapenemases are frequently co-produced by NDM-producing isolates.²³

New molecules

Together with the rediscovery of antibiotics which can retain anti-CRE activity, new molecules have been studied. Drugs which principally demonstrated to be appropriate for MDR organism are BLBLI combinations, but also other classes such as tetracyclines, cephalosporines and aminoglycosides have demonstrated to be non-inferior to carbapenems or penicillins for specific kind of infections.

BLI are molecules that can inhibit β -lactamases and carbapenemases restoring the activity of carbapenem or penicillin. Since resistance to clavulanate and sulbactam is recently increasing, 12 novel molecules as avibactam, vaborbactam and relebactam have been developed.

One of the most common carbapenemases produced by CRE are KPC. Therefore, many of these new molecules such as ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam are preferred treatment options for non-urinary CRE infections.

According to 2022 IDSA guidelines, the best treatment options for patients with CRE infections receiving medical care in countries with a high prevalence of metallo-lactamase-producing bacteria

include ceftazidime-avibactam plus aztreonam, or cefiderocol as monotherapy.²³

Ceftazidime-avibactam has in vitro activity against class A and D carbapenemases, but not against class B. IDSA recommendation for complicated infections which are sustained by non-class B CRE is based on several controlled trials showing non-inferiority of ceftazidime-avibactam compared to meropenem for UTI and IAI (RECLAIM trial), to doripenem for UTI (RECAPTURE trial) and to meropenem for nosocomial pneumonia (REPROVE trial).^{29,30,60}

Nevertheless, none of these trials are specific for CRE infection whose involvement is extremely variable ranging from 13% to 28%. The type of carbapenemases is not indicated as well.

Since ceftazidime-avibactam has not activity against class B carbapenemases, there is recent evidence that combination of avibactam with aztreonam is active against these isolates.⁶¹ That synergic combination is particularly interesting because while aztreonam evades class B carbapenemases activity, avibactam inhibits other enzymes which are often co-expressed, conferring a pan-anti-carbapenemases activity.⁶² A phase III trial testing aztreonam-avibactam is currently underway for class B CRE,⁶³ while some evidence exists suggesting ceftazidime-avibactam aztreonam as a useful clinical option.⁶⁴ Alongside, some KPC mutations have been detected which can confer resistance to ceftazidime-avibactam. These mutations such as KPC-3 and KPC-2 are expressed mainly by *K. Pneumoniae* but also by *E. Coli* and should be taken into account.⁶⁵

Anyway, ceftazidime-avibactam remains a useful option for treating serious KPC infections, even when used alone. This evidence is supported by many observational studies, even though further studies are needed to explore its effi-

Table 1 Outcome and side effects in clinical trials involving colistin.

Authors	Type of study	Comparison	Primary outcome/Major finding	Side effects	Notes
Cisneros et al., 2021	Randomized, controlled	Colistin vs. meropenem (both plus levofloxacin)	28-day mortality (23% vs. 25%)	Nephrotoxicity* (33% vs. 19%); CRRT* (9% vs. 2%)	Interrupted for excessive side-effects Heterogeneous isolated germs (16% <i>Pseudomonas Aeruginosa</i> , 16% <i>Acinetobacter</i> spp, 14% <i>Klebsiella</i> spp)
Motsch et al., 2020	Randomized, controlled	Imipenem-relebactam vs. imipenem plus colistin	Favorable overall response (71% vs. 70%)	Serious Adverse Events* (10% vs. 31%); Nephrotoxicity* (10% vs. 56%)	Isolated germs: 77% <i>Pseudomonas Aeruginosa</i> , 16% <i>Klebsiella</i> spp., 6% Other
van Duin et al., 2018	Subgroup analysis (CRACKLE trial)	Ceftazidime-avibactam vs. colistin	30-day mortality* (9% vs. 32%)	Nephrotoxicity (5% vs. 13%)	Enterobacteriaceae Most patients received additional anti-CRE agents as part of their treatment
Hakeam et al., 2020	Retrospective	Ceftazidime-avibactam vs. colistin	14-day mortality (19% vs. 31%)	Nephrotoxicity (9% vs. 10%); CRRT (6% vs. 10%)	Most patients received additional anti-CRE agents as part of their treatment (72% vs. 100%)
Feng et al., 2021	Retrospective	One effective antibiotic with or without aerosolized colistin	14-day clinical failure rate* (35% vs. 57%)	Newly onset dialysis* (4% vs. 13%)	Different number of patient in two group; 80% of infections caused by <i>Acinetobacter Baumannii</i>
Tumbarello et al., 2013	Retrospective	IV plus aerosolized colistin vs. IV colistin	Clinical cure rate* (69% vs. 55%)	New onset AKI (25% vs. 22%)	Days of mechanical ventilation* (8 vs. 12)

CRRT, continuous renal replacement therapy; AKI, acute kidney injury.

* $p < 0.05$.

cacy in nosocomial pneumonias and any potential survival benefits of prolonging its infusion to more than 3 h.⁶⁶

Meropenem-vaborbactam is a BLBLI active against KPC carbapenemase, but not against class B and D.

It was approved after TANGO I trial, which showed non-inferiority of meropenem-vaborbactam compared to piperacillin-tazobactam in patients with complicated UTI infections.⁶⁷ Its limit was not selecting patients with CRE infections, since nearly all the pathogens analysed were sensible to meropenem. It was followed by TANGO II, which finally analysed CRE infections, including BSI, pyelonephritis, ventilator-associated pneumonia (VAP), and cIAI, showing a decrease in mortality and adverse event.⁶⁸

A retrospective study by Ackley et al. shows no difference in clinical success when ceftazidime-avibactam or meropenem-vaborbactam are used in CRE infections.⁶⁹ Moreover, some evidence suggests in-vitro synergy for the combination of meropenem-vaborbactam and aztreonam for

the treatment of class B-producing CRE infections.^{63,70} Similarly, imipenem-relebactam is a recent drug combination approved by the FDA in 2019, which is only active against class A carbapenemases.

IDSA recommendations for mostly all CPE infection derive from RESTORE-IMI-1 and RESTORE-IMI2 trials.^{52,71} The first trial shows a better profile of imipenem-relebactam compared to imipenem plus colistin regarding clinical response rate, 28-day mortality rate and adverse events such as and treatment-associated nephrotoxicity. However, only 30% of pathogens involved were Enterobacteriaceae. The second trial shows non-inferiority of imipenem-relebactam in terms of 28-day mortality and clinical response, when compared with piperacillin-tazobactam, in patients with hospital acquired pneumonia (HAP) or VAP. Its in-vitro synergy with aztreonam has been demonstrated too (63).

Cefiderocol is a novel siderophore cephalosporin enters the bacterial wall due to its high affinity for several

penicillin-binding proteins, inhibiting cell wall formation. It represents an option for all Enterobacterales producing any of the five major carbapenemase enzymes.

Cefiderocol has a great safety profile, like other cephalosporins.⁷² European Medicines Agency (EMA) authorization includes MDR infections in patients with limited treatment options.⁷³ However, CREDIBLE-CR trial, which compares cefiderocol with the best available treatment shows an increase in all-cause mortality in the cefiderocol group treated for BSI, pneumonia and sepsis.⁷⁴

While these results seem to be due to the intrinsic mortality risk associated with *Acinetobacter* infections, the FDA has added a warning to its approval. At the same time, resistance to cefiderocol is starting to emerge and raising concern.⁷⁵ In this case in vitro evaluation of CRE susceptibility is of crucial role for the choice of appropriate antibiotic therapy.

Plazomicin is a novel aminoglycoside which binds 30 s subunit of bacterial ribosomes and inhibits protein synthesis.⁷⁶ Its spectrum of activity includes all carbapenemases but it is variably active against class B enzyme NDM-1.⁷⁷ This novel aminoglycoside is approved by FDA since 2019, when the CARE trial demonstrated a reduction of mortality and fewer adverse events in patients with CRE-UTI treated with plazomicin, compared to colistin plus meropenem or tigecycline.⁷⁸ Since the CARE trial was small, recommendations for BSI or pneumonia are not released. Plazomicin is not approved by EMA for financial reasons.

Eravacycline and omadacycline are tetracyclines with a broad spectrum of activity involving Gram-positive and Gram-negative bacteria except for *Pseudomonas*.⁶¹ In vitro analysis shows a greater sensibility when compared to tigecycline but they have more gastrointestinal adverse effect.⁷⁹ Since phase III trials shows non-inferiority when compared to carbapenems, linezolid or moxifloxacin, eravacycline and omadacycline are approved for CPE-sustained IAI, SSI and pneumonia.⁸⁰

As summarized, clinical options for the treatment of CPE infections are limited and all the antibiotics have a narrow spectrum of activity. The molecular pattern of each germ, which can be obtained rapidly, it's not reliable enough to determine clinical susceptibility to each molecule and in vitro analysis has to be provided.

Since that, waiting for controlled trial, a definition of the best available approach is hard to provide. Moreover, retrospective and observational study suggest controversial results about efficacy of monotherapy, and combination therapies have not been well defined yet. Generally, in severe infections when a CRE cause is suspected, empiric monotherapy seems to be insufficient and a combination therapy with the greatest coverage is judicious. Despite fast molecular definition, a rapid de-escalation should be performed only after in-vitro susceptibility analysis and monotherapy can be an option. However, the therapy should be always discussed individually and tailored depending on microbiological environment, type of patients and source of infection.

Conclusions

Since the emergency of MDR bacteria, clinicians used increasingly powerful antibiotics with broader spectrum.

The time necessary to conclude in vitro analysis of susceptibility leads to days of delay, during which unappropriated empiric therapy may facilitate resistance development. β -lactams and carbapenems have been continuingly used for their safety and activity but germs still manage to develop different resistance mechanisms which are nowadays hard to overcome.

ESBL-E and CRE are considered "supergerms" and are depicted as a microbiology priority. Finding a new application for non- β -lactam drugs is crucial to minimize further resistance development.

In this sense, the determination of molecular pattern of pathogens must be encouraged, as well as de-escalation.

Carbapenem-sparing strategy is a recent concept in treatment of infectious disease. The spread of CRE microorganisms has made this approach more urgent. The ultimate expansion of research towards novel molecules as BLBLI has enlarged therapeutic options but, depending their activity on molecular, lab and clinical details, their employ must be carefully examined. Similarly, novel tetracyclines and aminoglycosides are promising molecules because of their theoretic activity against a large group of ESBL and carbapenemases.

The complexity of susceptibility and germs resistance pattern is making infection control in the ICU increasingly challenging. The knowledge of the obstacles to overcome and of the limits and benefits of the available drugs will ensure antimicrobial monitoring and treatment for years to come.

Conflict of interest

The Authors of the study: "Treatment of severe infections caused by ESBL or carbapenemases-producing Enterobacteriaceae" ("Tratamiento de las infecciones severas causadas por Enterobacteriaceae productoras de beta lactamasas de espectro extendido (BLEE) y carbapenemasas.") has no conflict of interest.

References

1. Bush K. Proliferation and significance of clinically relevant betalactamases. *Ann N Y Acad Sci.* 2013;1277:84–90 <https://doi.org/10.1111/nyas.12023>
2. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. *Clin Microbiol Rev.* 2010;23(1):160–201 <https://doi.org/10.1128/CMR.00037-09>
3. Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al., EPIC III Investigators. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. *JAMA.* 2020;323(15):1478–87, <http://dx.doi.org/10.1001/jama.2020.2717>. PMID: 32207816.
4. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med.* 2021;47(11):1181–247, <http://dx.doi.org/10.1007/s00134-021-06506-y>. Epub 2021 Oct. 2. PMID: 34599691.
5. Harris PA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of piperacillin-tazobactam meropenem on 30-day mortality for patients with *E. coli* or *Klebsiella pneumoniae* blood stream infection and ceftriaxone resistance: a randomized clinical trial. *JAMA.* 2018;320:984–94.

6. Rodríguez-Baño J, Gutierrez-Gutierrez B, Pascual A. CON: carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales. *JAC-Antimicrob Resist.* 2021;3, dlaa112.
7. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al., WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis.* 2018;18(3):318–27, [http://dx.doi.org/10.1016/S1473-3099\(17\)30753-3](http://dx.doi.org/10.1016/S1473-3099(17)30753-3).
8. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis.* 2008;8(3):159–66, [http://dx.doi.org/10.1016/S1473-3099\(08\)70041-0](http://dx.doi.org/10.1016/S1473-3099(08)70041-0). PMID: 18291338.
9. Ambler RP, Coulson AF, Frere JM, Ghuysen JM, Joris B, Forsman M, et al. A standard numbering scheme for the class A betalactamases. *Biochem J.* 1991;276 Pt 1:269–70.
10. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother.* 2010;54(3):969–76 <https://doi.org/10.1128/AAC.01009-09>
11. Canton R, Coque TM. The CTX-M β -lactamase pandemic. *Curr Opin Microbiol.* 2006;9:466–75.
12. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, de Cueto M, Ríos MJ, et al. Bacteremia due to extended-spectrum beta-lactamase-producing *Escherichia coli* in the CTX-M era: a new clinical challenge. *Clin Infect Dis.* 2006;43(11):1407–14, <http://dx.doi.org/10.1086/508877>. Epub 2006 Oct 25. PMID: 17083012.
13. Rice L. Evolution and clinical importance of extended-spectrum β -lactamases. *Chest.* 2001;119 suppl 2:391S–6S.
14. Tamma PD, Rodríguez-Bano J. The use of noncarbapenem-lactams for the treatment of extended-spectrum-lactamase infections. *Clin Infect Dis.* 2017;2017:972–80.
15. Palacios-Baena ZR, Gutierrez-Gutierrez B, De Cueto M, Viale P, Venditti M, Hernández-Torres A, et al. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum- β -lactamase-producing Enterobacteriaceae. *J Antimicrob Chemother.* 2016;72:906–13.
16. Son SK, Lee NR, Ko JH, Choi JK, Moon SY, Joo E, et al. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. *J Antimicrob Chemother.* 2018;73:2631–42.
17. Darie AM, Khanna N, Jahn K, Osthoff M, Bassetti S, Osthoff M, et al. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial. *Lancet Respir Med.* 2022;S2213-2600(22):00086–8, [http://dx.doi.org/10.1016/S2213-2600\(22\)00086-8](http://dx.doi.org/10.1016/S2213-2600(22)00086-8). Online ahead of print.
18. Henderson A, Paterson DL, Chatfield MD, Tambyah PA, Lye DC, De PP, et al. Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin/tazobactam or meropenem from the MERINO study. *Clin Infect Dis.* 2021;73(11):e3842–50, <http://dx.doi.org/10.1093/cid/ciaa1479>. PMID: 33106863.
19. Bitterman R, Koppel F, Mussini C, Geffen Y, Chowers M, Rahav G, et al. Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). *BMJ Open.* 2021;11(2):e040210, <http://dx.doi.org/10.1136/bmjopen-2020-040210>. PMID: 33558347; PMCID: PMC7871690.
20. Seo YB, Lee J, Kim YK, Lee SS, Lee JA, Kim HY, et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. *BMC Infect Dis.* 2017;17(1):404, <http://dx.doi.org/10.1186/s12879-017-2502-x>. PMID: 28592240; PMCID: PMC5463388.
21. Chopra T, Marchaim D, Veltman J, Johnson P, Zhao JJ, Tansek R, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum- β -lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli*. *Antimicrob Agents Chemother.* 2012;2012:3936–42.
22. Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR, Hernández-Torres A, et al., REIPI-GEIRAS-FOREST group. Effectiveness of fosfomycin for the treatment of multidrug-resistant *Escherichia coli* bacteremic urinary tract infections: a randomized clinical trial. *JAMA Netw Open.* 2022;5(1):e2137277, <http://dx.doi.org/10.1001/jamanetworkopen.2021.37277>. PMID: 35024838.
23. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ, et al. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with Difficult-to-Treat Resistance (DTR-P. *aeruginosa*). *Clin Infect Dis.* 2022:ciac268, <http://dx.doi.org/10.1093/cid/ciac268>. Epub ahead of print. PMID: 35439291.
24. Portsmouth S, van Veenhuizen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. *Lancet Infect Dis.* 2018;18(12):1319–28, [http://dx.doi.org/10.1016/S1473-3099\(18\)30554-1](http://dx.doi.org/10.1016/S1473-3099(18)30554-1). Epub 2018 Oct 25. PMID: 30509675.
25. Russo A, Berruti M, Giacobbe DR, Vena A, Bassetti M. Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria. *Expert Rev Anti Infect Ther.* 2021;19(8):983–91, <http://dx.doi.org/10.1080/14787210.2021.1874918>. Epub 2021 Feb 17. PMID: 33596162.
26. Connolly LE, Riddle V, Cebrik D, Armstrong ES, Miller LG. A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis. *Antimicrob Agents Chemother.* 2018;62(4):e01989–17, <http://dx.doi.org/10.1128/AAC.01989-17>. Print 2018 Apr. PMID: 29378708.
27. Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, et al. Once-daily plazomicin for complicated urinary tract infections. *N Engl J Med.* 2019;380(8):729–40, <http://dx.doi.org/10.1056/NEJMoa1801467>. PMID: 30786187.
28. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and *Pseudomonas aeruginosa* complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. *Lancet Infect Dis.* 2016;16(6):661–73, [http://dx.doi.org/10.1016/S1473-3099\(16\)30004-4](http://dx.doi.org/10.1016/S1473-3099(16)30004-4). Epub 2016 Apr 20. PMID: 27107460.
29. Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections,

- including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. *Clin Infect Dis*. 2016;63(6):754–62, <http://dx.doi.org/10.1093/cid/ciw378>. Epub 2016 Jun 16. PMID: 27313268; PMCID: PMC4996135.
30. Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. *Lancet Infect Dis*. 2018;18(3):285–95, [http://dx.doi.org/10.1016/S1473-3099\(17\)30747-8](http://dx.doi.org/10.1016/S1473-3099(17)30747-8). Epub 2017 Dec 16. PMID: 29254862.
 31. Kollef MH, Nováček M, Kivistik Ü, Réa-Neto Á, Shime N, Martin-Loeches I, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. *Lancet Infect Dis*. 2019;19(12):1299–311, [http://dx.doi.org/10.1016/S1473-3099\(19\)30403-7](http://dx.doi.org/10.1016/S1473-3099(19)30403-7). Epub 2019 Sep 25. PMID: 31563344.
 32. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). *Lancet*. 2015;385(9981):1949–56, [http://dx.doi.org/10.1016/S0140-6736\(14\)62220-0](http://dx.doi.org/10.1016/S0140-6736(14)62220-0). Epub 2015 Apr 27. PMID: 25931244.
 33. Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-clAI). *Clin Infect Dis*. 2015;60(10):1462–71, <http://dx.doi.org/10.1093/cid/civ097>. Epub 2015 Feb 10. PMID: 25670823.
 34. Paterson DL, Bassetti M, Motyl M, Johnson MG, Castanheira M, Jensen EH, et al. Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacteriales: a subgroup analysis of the ASPECT-NP clinical trial. *J Antimicrob Chemother*. 2022;77(9):2522–31, <http://dx.doi.org/10.1093/jac/dkac184>. PMID: 35781341.
 35. Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae*: a pooled analysis of Phase 3 clinical trials. *J Antimicrob Chemother*. 2017;72(1):268–72, <http://dx.doi.org/10.1093/jac/dkw374>. Epub 2016 Oct 5. PMID: 27707990.
 36. Bassetti M, Vena A, Giacobbe DR, Falcone M, Tiseo G, Giannella M, et al. Ceftolozane/tazobactam for treatment of severe esbl-producing enterobacteriales infections: a multicenter nationwide clinical experience (CEFTABUSE II study). *Open Forum Infect Dis*. 2020;7(5):ofaa139, <http://dx.doi.org/10.1093/ofid/ofaa139>. PMID: 32462046; PMCID: PMC7237821.
 37. Stewart AG, Harris PNA, Chatfield MD, Littleford R, Paterson DL. Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacteriales (MERINO-3): study protocol for a multicentre, open-label randomised non-inferiority trial. *Trials*. 2021;22(1):301, <http://dx.doi.org/10.1186/s13063-021-05206-8>. PMID: 33888139; PMCID: PMC8060904.
 38. Nordmann P, Poirel L. Epidemiology and Diagnostics of carbapenem resistance in gram-negative bacteria. *Clin Infect Dis*. 2019;69 Suppl 7:S521–8, <http://dx.doi.org/10.1093/cid/ciz824>. PMID: 31724045; PMCID: PMC6853758.
 39. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629–55, [http://dx.doi.org/10.1016/S0140-6736\(21\)02724-0](http://dx.doi.org/10.1016/S0140-6736(21)02724-0). Epub 2022 Jan 19. PMID: 35065702; PMCID: PMC8841637.
 40. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. *Clin Microbiol Rev*. 2007;20(3):440–58, <http://dx.doi.org/10.1128/CMR.00001-07>. PMID: 17630334; PMCID: PMC1932750.
 41. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2001;45(4):1151–61, <http://dx.doi.org/10.1128/AAC.45.4.1151-1161.2001>.
 42. Walther-Rasmussen J, Høiby N. Class A carbapenemases. *J Antimicrob Chemother*. 2007;60(3):470–82, <http://dx.doi.org/10.1093/jac/dkm226>. Epub 2007 Jun 26. PMID: 17595289.
 43. Kazmierczak KM, Karlowsky JA, de Jonge BLM, Stone GG, Sahn DF. Epidemiology of carbapenem resistance determinants identified in meropenem-nonsusceptible enterobacteriales collected as part of a global surveillance program, 2012 to 2017. *Antimicrob Agents Chemother*. 2021;65(7):e0200020, <http://dx.doi.org/10.1128/AAC.02000-20>. Epub 2021 Jun 17. PMID: 33972241; PMCID: PMC8218680.
 44. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. *Curr Drug Metab*. 2009;10(1):13–21, <http://dx.doi.org/10.2174/138920009787048356>. PMID: 19149509.
 45. Johnston BD, Thuras P, Porter SB, Anacker M, VonBank B, Snippes Vagnone P, et al. Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant *Escherichia coli* isolates from the united states and international sites in relation to clonal background, resistance genes, coresistance, and region. *Antimicrob Agents Chemother*. 2020;64(10):e00797–20, <http://dx.doi.org/10.1128/AAC.00797-20>. PMID: 32718965; PMCID: PMC7508590.
 46. Seifert H, Blondeau J, Dowzicky MJ. In vitro activity of tigecycline and comparators (2014-2016) among key WHO' priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study. *Int J Antimicrob Agents*. 2018;52(4):474–84, <http://dx.doi.org/10.1016/j.ijantimicag.2018.07.003>. Epub 2018 Aug 21. PMID: 30012439.
 47. De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. *Crit Care*. 2014;18(3):R90, <http://dx.doi.org/10.1186/cc13858>. PMID: 24887101; PMCID: PMC4057423.
 48. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. *Clin Infect Dis*. 2005;40(9):1333–41, <http://dx.doi.org/10.1086/429323>. Epub 2005 Mar 22. Erratum in: *Clin Infect Dis*. 2006 Jun 15;42(12):1819. Dosage error in article text. PMID: 15825037.
 49. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. *Expert Rev Anti Infect Ther*. 2012;10(8):917–34, <http://dx.doi.org/10.1586/eri.12.78>. PMID: 23030331.
 50. Cisneros JM, Rosso-Fernández CM, Roca-Oporto C, De Pascale G, Jiménez-Jorge S, Fernández-Hinojosa E, et al., Magic Bullet Working Group WP1. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic

- Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. *Crit Care*. 2019;23(1):383, <http://dx.doi.org/10.1186/s13054-019-2627-y>. PMID: 31779711; PMCID: PMC6883535.
51. Motsch J, Murta de Oliveira C, Stus V, Köksal I, Lyulko O, Boucher HW, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. *Clin Infect Dis*. 2020;70(9):1799–808, <http://dx.doi.org/10.1093/cid/ciz530>. PMID: 31400759; PMCID: PMC7156774.
 52. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, et al., Antibacterial Resistance Leadership Group. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. *Clin Infect Dis*. 2018;66(2):163–71, <http://dx.doi.org/10.1093/cid/cix783>. PMID: 29020404; PMCID: PMC5850032.
 53. Feng JY, Peng CK, Sheu CC, Lin YC, Chan MC, Wang SH, et al. Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant gram-negative bacterial pneumonia: a multi-centre observational study. *Clin Microbiol Infect*. 2021;27(10):1465–73, <http://dx.doi.org/10.1016/j.cmi.2021.01.020>. Epub 2021 Feb 1. PMID: 33540113.
 54. Tumbarello M, De Pascale G, Trecarichi EM, De Martino S, Bello G, Maviglia R, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. *Chest*. 2013;144(6):1768–75, <http://dx.doi.org/10.1378/chest.13-1018>. PMID: 23989805.
 55. Rello J, Solé-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. *Clin Microbiol Infect*. 2017;23(9):629–39, <http://dx.doi.org/10.1016/j.cmi.2017.04.011>. Epub 2017 Apr 13. PMID: 28412382.
 56. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy*. 2019;39(1):10–39, <http://dx.doi.org/10.1002/phar.2209>. PMID: 30710469; PMCID: PMC7437259.
 57. Sutherland CA, Verastegui JE, Nicolau DP. In vitro potency of amikacin and comparators against *E. coli*, *K. pneumoniae* and *P. aeruginosa* respiratory and blood isolates. *Ann Clin Microbiol Antimicrob*. 2016;15(1):39.
 58. Castanheira M, Davis AP, Mendes RE, Serio AW, Krause KM, Flamm RK. In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant enterobacteriaceae and isolates carrying carbapenemase genes. *Antimicrob Agents Chemother*. 2018;62(8):e00313–18.
 59. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomicin. *Int J Infect Dis*. 2011;15(11):e732–9, <http://dx.doi.org/10.1016/j.ijid.2011.07.007>. Epub 2011 Sep 25. PMID: 21945848.
 60. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 Program. *Clin Infect Dis*. 2016;62(11):1380–9, <http://dx.doi.org/10.1093/cid/ciw133>. Epub 2016 Mar 8. PMID: 26962078; PMCID: PMC4872289.
 61. Maraki S, Mavromanolaki VE, Moraitis P, Stafylaki D, Kasi-mati A, Magkafouraki E, et al. Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo- β -lactamase-producing *Klebsiella pneumoniae*. *Eur J Clin Microbiol Infect Dis*. 2021;40(8):1755–9, <http://dx.doi.org/10.1007/s10096-021-04197-3>. Epub 2021 Feb 17. PMID: 33595756.
 62. Cornely OA, Cisneros JM, Torre-Cisneros J, Rodríguez-Hernández MJ, Tallón-Aguilar L, Calbo E, et al. Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. *J Antimicrob Chemother*. 2020;75(3):618–27, <http://dx.doi.org/10.1093/jac/dkz497>. PMID: 31828337; PMCID: PMC7021089.
 63. Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria. <https://clinicaltrials.gov/ct2/show/NCT03580044>.
 64. Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo- β -lactamase-producing enterobacteriales. *Clin Infect Dis*. 2021;72(11):1871–8, <http://dx.doi.org/10.1093/cid/ciaa586>. PMID: 32427286.
 65. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, et al. First Report of ceftazidime-avibactam resistance in a KPC-3-expressing *Klebsiella pneumoniae* isolate. *Antimicrob Agents Chemother*. 2015;59(10):6605–7, <http://dx.doi.org/10.1128/AAC.01165-15>. Epub 2015 Jul 20. PMID: 26195508; PMCID: PMC4576121.
 66. Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, et al. Ceftazidime-avibactam use for *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* infections: a retrospective observational multicenter study. *Clin Infect Dis*. 2021;73(9):1664–76, <http://dx.doi.org/10.1093/cid/ciab176>. PMID: 33618353.
 67. Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, et al. Effect of Meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. *JAMA*. 2018;319(8):788–99, <http://dx.doi.org/10.1001/jama.2018.0438>. PMID: 29486041; PMCID: PMC5838656.
 68. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, et al. Effect and Safety of Meropenem-vaborbactam versus best-available therapy in patients with Carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. *Infect Dis Ther*. 2018;7(4):439–55, <http://dx.doi.org/10.1007/s40121-018-0214-1>. Epub 2018 Oct 1. PMID: 30270406; PMCID: PMC6249182.
 69. Ackley R, Roshdy D, Meredith J, Minor S, Anderson WE, Capraro GA, et al. Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant enterobacteriaceae infections. *Antimicrob Agents Chemother*. 2020;64(5):e02313–19, <http://dx.doi.org/10.1128/AAC.02313-19>. PMID: 32094128; PMCID: PMC7179589.
 70. Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E. Searching for the optimal treatment for metallo- and serine- β -lactamase producing enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam. *Antimicrob Agents Chemother*. 2019;63(12):e01426–19,

- <http://dx.doi.org/10.1128/AAC.01426-19>. Epub ahead of print. PMID: 31570403; PMCID: PMC6879249.
71. Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study). *Clin Infect Dis*. 2021;73(11):e4539–48, <http://dx.doi.org/10.1093/cid/ciaa803>. PMID: 32785589; PMCID: PMC8662781.
 72. Katsube T, Echols R, Wajima T. Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin. *Clin Infect Dis*. 2019;69 Suppl 7:S552–8, <http://dx.doi.org/10.1093/cid/ciz828>. PMID: 31724042; PMCID: PMC6853762.
 73. Dimitrova EK. <https://www.ema.europa.eu/en/medicines/human/EPAR/fetcroja>, 2020. Accessed 8 Mar 2021.
 74. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. *Lancet Infect Dis*. 2021;21(2):226–40, [http://dx.doi.org/10.1016/S1473-3099\(20\)30796-9](http://dx.doi.org/10.1016/S1473-3099(20)30796-9). Epub 2020 Oct 12. PMID: 33058795.
 75. Yamano Y. In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria. *Clin Infect Dis*. 2019;69 Suppl 7:S544–51, <http://dx.doi.org/10.1093/cid/ciz827>. PMID: 31724049; PMCID: PMC6853761.
 76. Armstrong ES, Miller GH. Combating evolution with intelligent design: the neoglycoside ACHN-490. *Curr Opin Microbiol*. 2010;13(5):565–73, <http://dx.doi.org/10.1016/j.mib.2010.09.004>. PMID: 20932796.
 77. Eljaaly K, Alharbi A, Alshehri S, Ortwine JK, Pogue JM. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. *Drugs*. 2019;79(3):243–69, <http://dx.doi.org/10.1007/s40265-019-1054-3>. PMID: 30723876.
 78. McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, et al. Plazomicin for infections caused by carbapenem-resistant enterobacteriaceae. *N Engl J Med*. 2019;380(8):791–3, <http://dx.doi.org/10.1056/NEJMc1807634>. PMID: 30786196.
 79. Solomkin JS, Sway A, Lawrence K, Olesky M, Izmailyan S, Tsai L. Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance. *Future Microbiol*. 2019;14:1293–308, <http://dx.doi.org/10.2217/fmb-2019-0135>. Epub 2019 Oct 1. PMID: 31570004.
 80. Francisco EM. <https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/nuzyra>, 2019. Accessed 8 Mar 2021.